M
M. Emmy M. Dolman
Researcher at University of Amsterdam
Publications - 26
Citations - 793
M. Emmy M. Dolman is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Neuroblastoma & Cancer research. The author has an hindex of 10, co-authored 20 publications receiving 583 citations. Previous affiliations of M. Emmy M. Dolman include Utrecht University.
Papers
More filters
Journal ArticleDOI
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Thomas F. Eleveld,Derek A. Oldridge,Virginie Bernard,Jan Koster,Leo Colmet Daage,Sharon J. Diskin,Linda Schild,Nadia Bessoltane Bentahar,Angela Bellini,Mathieu Chicard,Eve Lapouble,Valérie Combaret,Patricia Legoix-Né,Jean Michon,Trevor J. Pugh,Lori S. Hart,JulieAnn Rader,Edward F. Attiyeh,Jun S. Wei,Shile Zhang,Arlene Naranjo,Julie M. Gastier-Foster,Michael D. Hogarty,Shahab Asgharzadeh,Malcolm A. Smith,Jaime M. Guidry Auvil,Thomas B.K. Watkins,Danny A. Zwijnenburg,Marli E. Ebus,Peter van Sluis,Anne Hakkert,Esther M. van Wezel,C. Ellen van der Schoot,Ellen M. Westerhout,Johannes H. Schulte,Godelieve A.M. Tytgat,M. Emmy M. Dolman,Isabelle Janoueix-Lerosey,Daniela S Gerhard,Huib N. Caron,Olivier Delattre,Javed Khan,Rogier Versteeg,Gudrun Schleiermacher,Jan J. Molenaar,John M. Maris +45 more
TL;DR: It is shown that RAS-MAPK pathway mutations may function as a biomarker for new therapeutic approaches to refractory disease and provide a rationale for genetic characterization of relapse neuroblastomas.
Journal ArticleDOI
Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours
Laurel T. Bate-Eya,Marli E. Ebus,Jan Koster,Ilona J.M. den Hartog,Danny A. Zwijnenburg,Linda Schild,Ida van der Ploeg,M. Emmy M. Dolman,Huib N. Caron,Rogier Versteeg,Jan J. Molenaar +10 more
TL;DR: Investigating the growth characteristics and confirmed tumour-forming potential of eight newly-derived neuroblastoma TICs cultured under serum-free conditions establish that they are relevant and useful Neuroblastoma tumour models.
Journal ArticleDOI
Cyclin-dependent kinase inhibitor AT7519 as a potential drug for MYCN-dependent neuroblastoma
M. Emmy M. Dolman,Evon Poon,Marli E. Ebus,Ilona J.M. den Hartog,Carel J. M. van Noesel,Yann Jamin,Albert Hallsworth,Simon P. Robinson,Kevin Petrie,Rolf W. Sparidans,Robbert J. Kok,Rogier Versteeg,Huib N. Caron,Louis Chesler,Jan J. Molenaar +14 more
TL;DR: AT7519 is a promising drug for the treatment of high-risk neuroblastoma patients with MYCN amplification, and improved efficacy of AT7519 observed in Th-MYCN mice correlated with higher tumor exposure to the drug.
Journal ArticleDOI
High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.
Laurel T. Bate-Eya,Ilona J.M. den Hartog,Ida van der Ploeg,Linda Schild,Jan Koster,Evan E. Santo,Ellen M. Westerhout,Rogier Versteeg,Huib N. Caron,Jan J. Molenaar,M. Emmy M. Dolman +10 more
TL;DR: It is shown that neuroblastoma cells might survive ABT199 treatment due to its acute upregulation of the anti-apoptotic BCL-2 family protein myeloid cell leukaemia sequence 1 (M CL-1) and BIM sequestration by MCL-1.
Journal ArticleDOI
Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma
Sally L. George,Sally L. George,Federica Lorenzi,David A. King,Sabine Hartlieb,James Campbell,Helen N. Pemberton,Umut H. Toprak,Karen Barker,Jennifer R. Tall,Barbara Martins da Costa,Marlinde L. van den Boogaard,M. Emmy M. Dolman,Jan J. Molenaar,Helen E. Bryant,Frank Westermann,Christopher J. Lord,Louis Chesler,Louis Chesler +18 more
TL;DR: It is found that ATRX inactivation results in increased DNA damage, homologous recombination repair (HRR) defects and impaired replication fork processivity, which results in specific DNA damage repair defects that can be therapeutically exploited.